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Vitamin K is a fat-soluble nutrient discovered in 1935 and its role in blood coagulation
has been thoroughly explored. In recent years, studies conducted in vitro and on animals
highlighted vitamin K involvement in brain cells development and survival. In particular,
vitamin K seems to have an antiapoptotic and anti-inflammatory effect mediated by the
activation of Growth Arrest Specific Gene 6 and Protein S. Moreover, this vitamin is
involved in sphingolipids metabolism, a class of lipids that participate in the proliferation,
differentiation, and survival of brain cells. An altered expression in sphingolipids profile
has been related to neuroinflammation and neurodegeneration. This review stems from
a growing interest in the role of vitamin K in brain functions, especially in cognition,
also in view of an expected increase of prevalence of Alzheimer’s disease and other
forms of dementia. It collects recent researches that show interesting, even though
not definitive, evidence of a direct correlation between vitamin K levels and cognitive
performance. Moreover, vitamin K antagonists, used worldwide as oral anticoagulants,
according to recent studies may have a negative influence on cognitive domains such as
visual memory, verbal fluency and brain volume. The aim of this review is to analyze the
evidence of clinical studies carried out up to date on the relationship between vitamin K
intake and cognitive performances. The involvement of vitamin K antagonists (VKAs) in
declining cognitive performances is also addressed separately.
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INTRODUCTION
Vitamin K is a fat-soluble nutrient mainly found in green leafy vegetables as phylloquinone
(Vitamin K1). This vitamin is widely known for its procoagulant effect. It acts as a cofactor for
the enzyme that allows the activation of vitamin K-dependent factors (II, VII, IX, X, protein C,
and protein S). A recent review collected studies that show its involvement in the metabolism of
the central nervous system (CNS), suggesting the possibility that a vitamin K deficiency might be
related to the onset of cognitive impairment (1).
These recently discovered functions, revealed that this vitamer participate in the enzymatic
activation of growth-arrest specific 6 protein (Gas-6) and protein S. The first has an anti-apoptotic,
mitogenic, and myelinating activity, the latter offers neuronal protection during ischemic/hypoxic
injury both in vivo and in vitro (2–4). Furthermore, vitamin K is known to be an inductor
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of sphingolipids synthesis. These polar lipids are an essential part
of CNS cell membrane and are linked to neuronal proliferation
and differentiation (1). Several studies are also investigating
the correlation between cognitive impairment and the use of
vitamin K antagonists (VKAs, i.e., warfarin, acenocoumarol,
and fluindion) as oral anticoagulants. In fact, these Coumarin
derivatives prevent the recycle of vitamin K after the G-
carboxylation (5).
Due to the progressive aging of global population, data
indicate that cases of dementia will double between 2020 and
2040, rising up to 81 million and consequently burdening
society and national health systems. For instance, Alzheimer’s
disease (AD) cases in the US will rise from 5.4 million up
to 13.8 million by mid-century (6, 7). Hence the importance
of identifying modifiable factors that could impact the course
of neurodegenerative pathologies. The aim of this review is to
analyze the evidence of clinical studies carried out up to date
examining the hypothesis of a cognitive decline among adults
with low serum levels or dietary intake of vitamin K. Moreover,
studies evaluating the potential link between VKAs and cognitive
functions were also included.
DEMENTIA AND COGNITIVE IMPAIRMENT
Dementia can be defined as a clinical syndrome of mental
capacity characterized by a substantial global decline in cognitive
function that is not attributable to altered consciousness; it
consists of a combination of symptoms attributable to various
causes or pathological events (8). Cognitive impairment is a
definition used in this review to indicate alterations in multiple
cognitive domains highlightable with standardized tests, as
clinically manifest dementia is often preceded by a heterogeneous
spectrum of cognitive performances (9).
It is difficult to find univocal data about the prevalence of
cognitive impairment and other forms of dementia (10); some
studies show that the global prevalence of dementia varies among
different countries, this could be related to a large number of
variables including education, mean age, socioeconomic level,
lack of a comparable methodology (11). However, it can certainly
be affirmed that the two most common type of dementia
in Western countries are Alzheimer’s disease (up to 60% of
cases) and vascular dementia (up to 20% of cases). These two
forms of dementia are easily mistaken one for another due to
their similarities in symptomatology, pathophysiology, and risk
factors (12).
The mechanism underlying Alzheimer’s disease is the
deposition of β-amyloid peptide (Aβ) and the neurofibrillary
tangles of the microtubule binding protein tau. In particular,
Aβ peptides are responsible for the massive neuronal death that
defines the disease (13).
A few studies concluded that Vitamin K seems to prevent Aβ-
induced apoptosis through the activation of Gas-6, showing a
pro-survival effect on brain cells (14).
Regarding vascular dementia, the main causes are represented
by several vascular pathologies that result in cerebral ischemia.
Studies published in the last years have attributed to Protein
S (activated by vitamin K) a role in improving post-ischemic
cerebral blood flow (15) and potentially leading to a more
favorable cognitive outcome.
VITAMIN K STRUCTURE AND FUNCTION
Vitamin K can be found as phylloquinone (the main dietary
source of vitamin K) and it’s also identified as menaquinones
(vitamin K2) which include several vitamers of bacterial origin
(2). Menaquinone-4 (MK-4) is the most represented vitamer in
both human and rats’ brains (16, 17).
MK-4 seems to protect against oxidative damage and
inflammatory cascade activation in in vitro studies (18, 19). In
addition, in murine models MK-4 depletion has been found
correlated with worse cognitive performances (20).
Vitamin K is widely known for its role in blood coagulation as
the cofactor of G-glutamyl carboxylase that allows the activation
of vitamin K-dependent factors such as factor II, VII, IX, X,
protein C, and protein S. Vitamin K is also involved in the
G-carboxylation of two vitamin K-dependent proteins whose
activity contributes to an adequate cerebral homeostasis, namely
Gas-6 and protein S (3, 4). Moreover, vitamin K participates
as a cofactor in the synthesis of sphingolipids, an important
constituent of brain cells membrane (21). Several studies
conducted on in vitro and murine models have highlighted the
role of these constituents in brain metabolism. In some cases, a
correlation with neurodegenerative diseases emerged that could
be further examined trough human studies.
Gas-6
Gas-6 has a central role in the development and survival
of nervous system. In addition, it shows an anti-apoptotic,
mitogenic, andmyelinating activity in neuronal and glial cells (1).
Gas-6 binds and activates the receptor tyrosine kinases
of the Tyro3, Axl, and Mer (TAM) family. Axl is involved
in the proliferation of numerous cell types and in the
survival of gonadotropin-releasing hormone (GnRH) neurons
allowing their migration from the olfactory bulb to the
hypothalamus (22, 23).
Mer protects primary macrophages from oxidative stress
induced-apoptosis (24).
The specific role of Tyro3 in cell survival is yet to be defined,
but activities similar to Axl have been observed concerning the
migration of GnRH neurons A (25–27).
An in vitro study revealed that recombinant Gas-6 protects
hippocampal rats’ neurons from apoptosis, underlining the pro-
survival effect of this protein through the activation of TAM
proteins (28).
Through the activation of Axl and phosphatidylinositol
3-kinase (PI3K) pathways, Gas-6 modulates oligodendrocyte
survival and microglial phenotype both in vitro and in vivo
(3) preventing tumor necrosis factor alpha-induced apoptosis.
A study on cuprizone-induced demyelination model (adopted
as a model of multiple sclerosis) revealed that the deletion
of Gas-6/Axl signaling leads to prolonged neuroinflammation
with axonal damage and consistent demyelination (29, 30). This
immune-regulatory role links Gas-6 to autoimmune disorders,
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more specifically to the pathogenesis of multiple sclerosis
(MS) (31, 32).
Studies developed using murine culture of microglial cells
showed that Gas-6 downregulates the expression of Interleukin-
1b e induced nitric oxide synthase, thereby reducing the
proinflammatory response (33). Two recent murine models
using knock-out mice for Mer and Axl, demonstrated a reduced
recruitment of microglial cells to neuronal sites of injury,
also affecting the phagocytic activity through cytoskeleton
changes (34, 35).
Furthermore, Gas-6 has shown a decrease of ß-amyloid-
induced apoptosis, a hallmark of Alzheimer’s disease, through the
inhibition of low-voltage Ca2+ influx channels (14). However, a
more recent study found that Gas-6 inhibits Tyro3 whose effects
prevent β-amyloid deposition (36).
Protein S
Historically protein S has been known for its anticoagulant effect,
but recent studies are exploring further effects, such as a possible
role in inflammation, angiogenesis, and cancer (37). As well as in
ameliorating post-ischemic cerebral blood flow (15).
Protein S shares with Gas-6 almost half of its amino acid
structure (44%) (4), and consequently it performs part of
its actions as a TAM receptor ligand. Zhu et al. showed a
direct correlation between the inhibition of Tyro3/Akt signaling
pathway and the hypoxic-induced apoptosis of hippocampal
neurons, underlining a potential protective effect of protein S in
cerebral infarct (38). In particular, protein S has a protective effect
against NMDA-induced toxicity and apoptosis via the Tyro3/Akt
pathway (39). This finding may suggest a possible role of protein
S as an adjunct of tissue Plasminogen Activator to reduce
cerebral post-ischemic toxicity (40), without increasing the risk
of bleeding when administered alone in high concentration to
stroke rodent models (15). An additional property of protein
S seems to be the preservation of the integrity of the blood-
brain barrier (BBB) as it operates as a safeguard against chronic
ischemic damage and BBB-related disorders (41).
Sphingolipid Metabolism
Sphingolipids is one of the major classes of eukaryotic lipids and
an essential component of cell membranes and their synthesis is
known to be induced by vitamin K (21).
The sphingolipids most frequently observed in neuronal
cell membranes are ceramides, sphingomyelin, cerebrosides,
sulfatides, and gangliosides (42). This class of lipids seems to be a
vital modulator of cell proliferation, differentiation, and survival
(43). A growing amount of evidence are associating sphingolipids
metabolism to the pathophysiology of CNS diseases. These
polar lipids have been related to a neuroinflammatory and
neurodegenerative states due to microglial activation and
accumulation of amyloid precursor protein (APP) (44).
These are at the basis of the development of several
pathologies like AD (43, 45), where inflammation is a
consequence of microglial activation triggered by β-amyloid
plaques (46).
Lastly, sphingolipids guide the process of myelination in the
CNS and are themselves major components of oligodendrocyte
membrane. In the serum and cerebrospinal fluid of patients
affected by multiple sclerosis antibodies have been detected
against myelinic sphingolipids (47, 48) along with ceramide
accumulation in active lesions (49).
The Assessment of Vitamin K Status
Both biomarkers and questionnaires have been suggested
to evaluate vitamin K status. Circulating phylloquinone can
be measured with high performance liquid chromatography
(HPLC) a method that responds to changes in dietary
phylloquinone intake. Serum phylloquinone should be measured
in fasting samples to better reflect overall nutritional status.
Moreover, vitamin K serum levels are influenced by serum
triglycerides and should be corrected accordingly. There is
currently no established threshold of circulating phylloquinone
that indicates insufficiency or deficiency (50).
Other circulating markers are: PIVKA-II (protein induced by
vitamin K absence-II) that has shown low sensitivity to dietary
variation of vitamin K; undercarboxylated fraction of osteocalcin
(unOc) and desphospho-uncarboxylatedmatrix Gla-protein (dp-
ucMGP) that are both more sensitive than PIVKA-II but still
conditioned by factors such as age and the total amount of matrix
Gla-proteins available (50).
Vitamin K intake can be assessed with questionnaires such as
the food frequency questionnaire (FFQ) or dietary records.While
being efficient in terms of costs and time and easy to implement,
questionnaires rely on the recall ability and perceptions of
individuals’ diet and therefore may be subjected to bias (51).
Considering the lack of a single gold standard measure, and
the limitations affecting the available methods, vitamin K status
may be best assessed with a combination of both questionnaires
and biomarkers (50).
VKAS-BRAIN RELATIONSHIP
VKAs exercise their function by blocking the activity of vitamin
K oxidoreductase (VKOR) preventing the recycle of vitamin K
after the G-carboxylation (5). The possibility of an adverse impact
of VKAs on the brain has been evident since the finding of
abnormalities of the CNS in newborns exposed to warfarin or
other coumarin derivatives (52). However, detailed mechanisms
are yet to be comprehended. Studies on whether Gas-6 and
protein S G-carboxylation are impaired by VKAs in the human
brain have not yet been conducted. Studies performed on murine
models have shown how VKAs determine a decrease in MK-
4 brain concentrations, the most represented vitamer in rats’
brain (16). Nagakawa et al. identificated the enzyme responsible
for the conversion of phylloquinone in MK-4 (UBIAD1) (17)
and Tamadon-Nejad et al. demonstrated that despite an excess
of phylloquinone in rats’ brain, MK-4 brain concentrations
remained low in warfarin treated rats suggesting an alteration of
the MK-4 biosynthetic pathway in the presence of warfarin (53).
Moreover, rats treated with VKAs showed worse performances in
tests to evaluate their cognitive and behavioral functions (53, 54).
It is well known how anticoagulant use can decrease the risk
of dementia by reducing the number of cerebral ischemic events
in AF patients (55).
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Mostaza et al. observed that in a population taking
vitamin K antagonists, there was a trend toward higher
warfarin prescription among patients with cognitive impairment,
regardless dependency or frailty. Thus, a thorough evaluation
on the association between non-vitamin K antagonists oral
anticoagulants (NOACs) use and cognitive decline is crucial (56).
A recent meta-analysis found a borderline significant
association between the use of NOACs and the lower risk
of cognitive impairment when compared with VKAs and
acetylsalicylic acid (57).
Similar findings were observed in other studies where NOAC
were considered an optimal or even better alternative to warfarin,
due to their lower bleeding risk and variability in anticoagulation
effect (58). A previous study validated the same hypothesis:
NOACs provide a better protection against atrial fibrillation-
related stroke in terms of lower risk of cerebral ischemic events
and new-onset dementia than those treated with warfarin (59).
VITAMIN K AND COGNITIVE DECLINE
Considering the numerous roles of Vitamin K highlighted in the
previous studies, in recent years some authors have started to
investigate the potential link between cognitive impairment and
vitamin K.
Whether vitamin K deficiency is associated to cognitive
decline is still a matter of debate today. From the literature search,
we were able to include 7 human studies and all, except one
(60), confirmed an association between vitamin K and cognitive
function among older adults (Table 1).
Six studies demonstrated, in a population of 65 years and
older, a direct correlation between low vitamin K dietary
intake or serum concentration and deteriorated cognitive and
behavioral performances. In particular, Presse et al. in 2013
published the results of a cross sectional study conducted
on 320 elderly, aged 70–85, free of cognitive impairment
from the NuAge study cohort (63). Phylloquinone serum
concentration analysis was measured using High performance
liquid chromatography (HPLC), a method already validated as
an indicator of dietary phylloquinone intake over a long period of
time. Circulating phylloquinone concentrations are conditioned
by the blood lipid profile that needs to be assessed as well
while using HPLC (67). Cognitive assessment was performed
using specific tests for each cognitive domain (verbal and
non-verbal episodic memory, executive functions, and speed
of processing). Results showed that recruited subjects with
higher serum phylloquinone performed better in verbal episodic
memory, while no correlation was found with non-verbal
episodic memory, executive functions, and speed of processing,
underlining the role of vitamin K in memory consolidation (63).
These results are supported by a previous murine model where
rodents underwent a 5-days learning test in the Morris Water
Maze and those fed with lower vitamin K levels required longer
time to perform the task compared to those adequately fed (20).
Two studies evaluated vitamin K intake using a semi
quantitative food frequency questionnaire (FFQ). They observed
a less severe subjective memory complaint (65) as well as a better
cognition and less behavioral disturbances (64) among geriatric
patients with higher vitamin K intake. The FFQ is a 50 items
questionnaire that aims to evaluate vitamin K dietary intake.
Although it has been validated in elderly people (68) it may result
in an underestimation when investigating patients with cognitive
decline. Therefore, the FFQ may not be as representative of
phylloquinone intake as its serum levels measured with HPLC in
this specific circumstance.
In line with previous studies, Kiely et al. described that
elderly with poor cognitive functions, evaluated with MMSE,
had the lowest dietary vitamin K intake (assessed with FFQ).
Similar results were observed correlating MMSE scores and
phylloquinone serum levels measured with HPLC (66).
Further publications highlighted the potential role of
this vitamer among patients with Alzheimer’s disease-related
dementia (61, 62), who were found with significant lower levels
of vitamin K even after data were adjusted for energy intakes. In
particular, Presse et al. reported in 2008 how vitamin K intake,
evaluated with 3–5 days diet records, were notably lower in
patients with early stages of AD. Partially limiting the strength
of this study are the diet records used, as they show limited value
for the assessment of vitamin K intake (62).
Opposite results were obtained by Van Den Heuvel et al.
(60) in a middle-age sample (55–65 years) of 599 individuals,
measuring vitamin K in an indirect way through levels of
desphospho-uncarboxylated matrix Gla-protein (dp-ucMGP).
Over the 6 years follow up, no significant association between
vitamin K and cognitive decline was found. The recruitment
criterion of a different age group may be the reason why
contrasting results were observed, since the brain might be
susceptible to nutrient deficiency in different ways at different
times in life (20). Moreover, as stated by the authors themselves,
dp-ucMGP may not be the most suitable marker of vitamin K
levels in the brain (60).
An emerging issue is how the use of VKAs could influence
brain metabolism and this topic is analyzed separately. The few
papers published until now point out, to a limited extent, a
potential correlation between the use of VKAs and both cognitive
decline and brain focal atrophies (Table 2).
Ferland et al. observed in a large cohort study a significant
decrease in visual memory and verbal fluency among patients
treated with VKAs when compared to individuals under no
blood-thinning treatment, but no association was observed
between the global cognitive function and VKAs use over at 10
years follow up (70).
Brangier et al. analyzed the brain volume, using 3 or 1.5 Tesla
MRI, of 54 subjects (18 under VKAs treatment and 36 matched
controls) and found a significant inverse correlation between the
duration of drug exposure and gray/white matter volume in the
right frontal inferior operculum, right precuneus, and left middle
frontal gyrus (71). The same author found an important decline
in executive functions (assessed with frontal assessment battery)
among geriatric patients treated with VKAs over at 24 months
follow up. It’s worth noticing how, in the same study, decline
in Mini mental state examination (MMSE) scores, used as an
assessment of cognitive performance, was not found significantly
associated with VKAs use over the same period of time (72).
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Lastly, Annweiler et al. in 2015 reported a 15% higher risk of
cognitive impairment in patients treated with fluindione which
is used as an anticoagulant drug. The positive association (not
observed in patients treated with warfarin or acenocoumarol)
remained statistically significant even after adjustment for
covariables (69).
Clinical studies have suggested that VKAs use does not affect
vitamin K plasma concentration (73) and involved molecular
patterns that might lead to cognitive impairment in humans
using VKAs are yet to be comprehended.
When implying an involvement of VKAs in cognitive
impairment it must be considered that patients are under
treatment for pathologies like atrial fibrillation, that can possibly
influence, to some level, mental deterioration (74).
CONCLUSIONS
The present review stems from a growing interest in the role of
vitamin K in brain function, especially in cognition. It collected
recent contributions to the topic, showing interesting, even
though not definitive, evidence of direct correlation between
vitamin K levels and cognitive performance. Moreover, VKAs
might influence negatively some cognitive domains such as visual
memory and verbal fluency and the brain volume. Only a small
number of publications were based on studies performed on
humans, limiting the amount of papers included. These studies
were heterogeneous in several ways: study design, markers
used to measure vitamin K levels, method used to assess
cognitive performance and age of patients included in the studies.
Further evidence should be gathered using more standardized
methodology to foster comparability of results.
The paucity of published papers suggests the need of a more
thorough investigation from the scientific community, using
randomized trials with large samples to confirm the hypothesis
that low vitamin K can be associated to cognitive decline.
A standardized methodology for both cognitive evaluation
and vitamin K dietary intake and serum concentrations
must be adopted in order to develop more comparable and
reliable data.
Due to the large number of individuals treated with VKAs,
a large prospective study is possible and could be crucial to
elucidate the influence of these drugs on vitamin K serum levels
and consequently on cognitive decline.
In conclusion, considering the growing social and economic
burden linked to the increasing number of patients suffering
from cognitive impairment and dementia, further researches on
this topic can prove to be beneficial and applicable results can
be expected.
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